Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 376 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Receptors Chimeric Antigen Clear all
Completed Phase 1 Interventional Results available

Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

NCT04088890
View directory record Official record
Conditions
B-ALL, B-cell Non Hodgkin Lymphoma, DLBCL, Follicular Lymphoma Grade 3B
Interventions
Fludarabine, Cyclophosphamide, CD22 CAR
Drug
Lead sponsor
Matthew Frank
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Completed Phase 1 Interventional

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

NCT04088864
View directory record Official record
Conditions
B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma
Interventions
Fludarabine, Cyclophosphamide, Autologous CD22 CAR T
Drug
Lead sponsor
Kara Lynn Davis
Other
Eligibility
1 Year to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Recruiting Phase 1 Interventional

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

NCT04545762
View directory record Official record
Conditions
Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Diffuse Large B Cell Lymphoma, Small Lymphocytic Lymphoma, Transformed Lymphoma, Non-Hodgkin Lymphoma
Interventions
Fludarabine, Cyclophosphamide, anti-CD19 CAR-T cells
Drug · Biological
Lead sponsor
C. Babis Andreadis
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Recruiting Phase 1 Interventional

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

NCT06408194
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia
Interventions
CD22CART infusion, Tisagenlecleucel
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 25 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Recruiting Phase 1 Interventional

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

NCT06815029
View directory record Official record
Conditions
Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma
Interventions
Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Echocardiography, Fludeoxyglucose F-18, Intracranial Catheter Placement, Leukapheresis, Magnetic Resonance Imaging, Positron Emission Tomography, Resection
Procedure · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Recruiting Phase 2 Interventional

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

NCT05934448
View directory record Official record
Conditions
Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma Refractory, Primary Mediastinal Large B-Cell Lymphoma Recurrent, Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
Pembrolizumab, Lymphodepletion Chemotherapy, Chimeric Antigen Receptor (CAR) Therapy Infusion, Leukapheresis
Drug · Procedure
Lead sponsor
Jennifer Crombie, MD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Recruiting Phase 3 Interventional

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

NCT07648264
View directory record Official record
Conditions
Secondary Immune Deficiency
Interventions
IgPro20
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
17
States / cities
Orange, California • Denver, Colorado • Coral Springs, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Recruiting Phase 2 Interventional

Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

NCT07042438
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Axicabtagene Ciloleucel, Biospecimen Collection, Chemotherapy, Fecal Microbiota Transplantation, Leukapheresis, Placebo Administration
Biological · Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

NCT06121297
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Nephritis
Interventions
CABA-201
Biological
Lead sponsor
Cabaletta Bio
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
21
States / cities
Orange, California • Sacramento, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma

NCT03568461
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
tisagenlecleucel
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
9
States / cities
Duarte, California • San Francisco, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Dexamethasone, Lenalidomide, Cilta-cel, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
19
States / cities
San Francisco, California • New Haven, Connecticut • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Recruiting Phase 1 Interventional

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

NCT06287528
View directory record Official record
Conditions
Philadelphia-Negative ALL, Philadelphia-Positive ALL, Relapsed ALL, Adult, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoid Leukemia in Relapse
Interventions
19-28z/IL-18 CAR T cells
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
17 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Recruiting Phase 1 Interventional

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

NCT06305299
View directory record Official record
Conditions
Ovary Neoplasm, Ovarian Cancer, Epithelial Ovarian Cancer, Recurrent
Interventions
iC9-CAR.B7-H3 T cells, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Not yet recruiting Phase 1 Interventional

A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)

NCT07848295
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions
BMS-986527, Nivolumab, Cabozantinib
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
New Haven, Connecticut • Basking Ridge, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Trial of ADI-270 in ccRCC

NCT06480565
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
ADI-270, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Adicet Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Active, not recruiting Phase 1 Interventional

iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma

NCT01953900
View directory record Official record
Conditions
Osteosarcoma, Neuroblastoma
Interventions
GD2 T cells, VZV vaccine, Fludarabine, Cyclophosphamide
Genetic · Biological · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2034
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Enrolling by invitation Phase 1 Interventional

CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

NCT07168486
View directory record Official record
Conditions
B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Follicular Lymphoma, Transformed Follicular Lymphoma (tFL), Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter Transformation, Marginal Zone Lymphoma
Interventions
CD19.20.22 CAR T cells, Fludarabine and Cyclophosphamide
Biological · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Active, not recruiting Phase 1 Interventional

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors

NCT05103631
View directory record Official record
Conditions
Liver Cell Carcinoma, Solid Tumor, Wilms Tumor, Malignant Rhabdoid Tumor, Yolk Sac Tumor, Rhabdomyosarcoma, Liposarcoma, Embryonal Sarcoma of the Liver
Interventions
CATCH T cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2040
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Recruiting Phase 1 Interventional

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

NCT07333261
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BMS-986453
Drug
Lead sponsor
Susan Bal
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2041
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Recruiting Not applicable Interventional

A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

NCT05621291
View directory record Official record
Conditions
B-All, Acute Lymphoblastic Leukemia
Interventions
NGS testing
Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Recruiting Phase 1 Interventional

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

NCT07509034
View directory record Official record
Conditions
Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Recurrent or Refractory, Solid Tumors
Interventions
Autologous B7-H3 CAR T, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Recruiting Phase 3 Interventional

Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

NCT06652633
View directory record Official record
Conditions
Hematological Malignancies
Interventions
GLPG CAR T-cell therapy
Genetic
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

NCT06733935
View directory record Official record
Conditions
Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis
Interventions
NKX019, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Nkarta, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
16
States / cities
Orange, California • Gainesville, Florida • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 1, 2026, 2:27 AM EDT
Recruiting Phase 1 Interventional

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

NCT06096038
View directory record Official record
Conditions
Head and Neck Cancer, Relapse, Recurrent, Refractory Cancer
Interventions
Cyclophosphamide, Fludarabine, Cell Therapy
Drug · Biological
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 1, 2026, 2:27 AM EDT